Kristin Brooks01.23.14
Merrimack Pharmaceuticals has initiated a Phase I dose-escalating trial of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors. Preclinical research suggests MM-398 administration results in sustained delivery of larger quantities of chemotherapy as compared to conventional administration.
The Phase I study will assess the safety of MM-398 and will determine the recommended Phase II dose. Approximately 40 patients from 1 to 21 years are expected to be enrolled.
The Phase I study will assess the safety of MM-398 and will determine the recommended Phase II dose. Approximately 40 patients from 1 to 21 years are expected to be enrolled.